QIMA Life Sciences has launched SQINGEVITY, a testing platform that follows a proposed cosmetic mechanism from cell culture through human skin explants to clinical studies in volunteers. Its Longevity SCORE quantifies protein carbonylation — oxidative damage to proteins linked to impaired proteostasis — in ex vivo skin, converting it to a 0–100 value. The development signals a shift from marketing-led antiaging language toward measurable biological endpoints, while the testing remains commissioned and funded by the companies making the claims.
Key Points
- Platform links cell culture, skin explants and clinical volunteer studies
- Longevity SCORE quantifies protein carbonylation, a marker of oxidative damage
- Testing is commissioned and paid for by claim-making manufacturers
Longevity Analysis
Skin is the most visible readout of cumulative oxidative burden, and protein carbonylation reflects the same proteostatic decline occurring in tissues that are far harder to sample. A credible measurement standard for topical and ingestible interventions would give practitioners a way to separate demonstrated effect from plausible mechanism — the same discrimination required across the wider healthy-aging market. The caution worth holding is structural: a single damage marker in excised tissue cannot stand in for regenerative capacity, barrier defense or the systemic processes that produce visible aging in the first place.
Original published by Longevity.Technology, by Eleanor Garth.